


wherein **E**, **D**, **G**, **T** and **R**¹ are as defined herein and wherein **Hal** is Cl or Br

and wherein **X** is –B(OH)₂, -boronic acid pinacolester, -trifluoroborate or –SNBu₃

and wherein **PG** is a protecting group selected from the group consisting of benzyl, 1-phenylethyl, 1-(4-methoxyphenyl)ethyl.

In another aspect, there is provided an intermediate compound selected from the group consisting of

formula 10.2




In another aspect, there is provided the compound as defined herein for use in the treatment of a disease which can be treated by inhibition of the SYK enzyme.

In another aspect, there is provided the compound as defined herein for use in the treatment of a disease selected from the group consisting of allergic rhinitis, asthma, COPD, adult respiratory distress syndrome, bronchitis, B-cell lymphoma, dermatitis and contact dermatitis, allergic dermatitis, allergic rhinoconjunctivitis, rheumatoid arthritis, anti-phospholipid syndrome, Berger's disease, Evans's syndrome, ulcerative colitis, allergic antibody-based glomerulonephritis, granulocytopenia, Goodpasture's syndrome, hepatitis, Henoch-Schönlein purpura, hypersensitivity vasculitis, immunohaemolytic anaemia, autoimmune haemolytic anemia, idiopathic thrombocytopenic purpura, Kawasaki syndrome, allergic conjunctivitis, lupus erythematoses, lupus nephritis, capsule cell lymphoma, neutropenia, non-familial lateral sclerosis, arteriosclerosis, Crohn's disease, multiple sclerosis, myasthenia gravis,

Patent Claims

1. Compound of formula 1



wherein

A is selected from the group consisting of N and CH

D is CH,

E is selected from the group consisting of C and N,

T is C

G is selected from the group consisting of C and N,

and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system,

and wherein

M is selected from the group consisting of -CH₂-, -O-, -NH- and -N(C₁₋₄-alkyl)-;

R³ is selected from the group consisting of methyl and ethyl;

Het is selected from the group consisting of

a five- to six-membered monocyclic heterocycle with 1, 2, 3 or 4 heteroatoms each independently from one another selected from N, S and O,

and a nine- to eleven-membered bicyclic heterocycle with 1, 2, 3 or 4 heteroatoms each independently from one another selected from N, S and O;

Hetaryl is selected from the group consisting of

a five- to six-membered monocyclic heteroaromate with 1, 2, 3 or 4 heteroatoms each independently from one another selected from N, S and O;

and a nine- to eleven-membered bicyclic heteroaromate with 1, 2, 3 or 4 heteroatoms each independently from one another selected from N, S and O;

and wherein

R¹ is selected from the group consisting of

C₆₋₁₀-aryl, Het and Hetaryl;

which is further substituted by one, two or three substituents **Z**,

whereby each **Z** independently is a substituent selected from the group consisting of

H, -OH, oxo, -CN, halogen, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -C₁₋₆-haloalkyl, three- to seven-membered cycloalkyl, **Het**, **Hetaryl**, -CO-N(CH₃)₂, -CO-NHCH₃, -CO-NH₂, -(C₁₋₃-alkylene)-O-(C₁₋₃-alkyl), -O-**Het**,


which is further substituted by one, two or three substituents **X**,

whereby each **X** independently is selected from the group consisting of H, halogen, -OH, oxo, -C₁₋₄-alkyl, -O-C₁₋₄-alkyl, -C₁₋₄-haloalkyl, -O-(C₁₋₄-alkylene)-**Het**, **Het**, **Hetaryl**, -NH₂, -NH(CH₃), -N(CH₃)₂,

whereby substituent **X** is further substituted by one, two or three substituents of a group selected from H, oxo, -OH, halogen and C₁₋₃-alkyl, n-butyl, isobutyl and tert-butyl,

and the pharmaceutically acceptable salts of the aforementioned compounds.

2. The compound of formula **1'**



wherein **A**, **M**, **D**, **E**, **T**, **G**, **Het**, **Hetaryl**, R^1 and R^3 are defined according to claim 1,
and the pharmaceutically acceptable salts of the aforementioned compounds.

3. The compound of formula **1** according to claim 1 or of formula **1'** of claim 2, wherein

D is CH

and wherein **E** is N

and wherein

M is $-CH_2-$

and wherein

R^3 is methyl,

and wherein

G is C (carbon)

R^1 is selected from the group consisting of

phenyl, **Het** and **Hetaryl**;

which is further substituted by one, two or three substituents **Z**,

whereby each **Z** independently is a substituent selected from the group consisting of

H, -OH, oxo, -CN, halogen, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -C₁₋₆-haloalkyl, three- to seven-membered cycloalkyl, **Het**, **Hetaryl**, -CO-N(CH₃)₂, -CO-NHCH₃, -CO-NH₂, -(C₁₋₃-alkylene)-O-(C₁₋₃-alkyl), -O-**Het**,


which is further substituted by one, two or three substituents **X**,

whereby each **X** independently is selected from the group consisting of H, halogen, oxo, -C₁₋₄-alkyl, -O-C₁₋₄-alkyl, -C₁₋₄-haloalkyl, -O-(C₁₋₄-alkylene)-**Het**, **Het**, **Hetaryl**, -NH₂,


whereby substituent **X** is further substituted by one, two or three substituents of a group selected from H, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl,

and the pharmaceutically acceptable salts of the aforementioned compounds.

4. The compound of formula **1a** according to claim 1



or of formula **1a'** according to claim 2,



wherein

R¹ is selected from the group consisting of

phenyl, **Het** and **Hetaryl**;

which is further substituted by one, two or three substituents **Z**,

whereby each **Z** is independently a substituent selected from the group consisting of

H, -OH, oxo, -CN, halogen, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -C₁₋₆-haloalkyl, three- to seven-membered cycloalkyl, **Het**, **Hetaryl**, -CO-N(CH₃)₂, -CO-NHCH₃, -CO-NH₂, -(C₁₋₃-alkylene)-O-(C₁₋₃-alkyl), -O-**Het**,

which is further substituted by one, two or three substituents **X**,

whereby each **X** is independently selected from the group consisting of H, halogen, oxo, -C₁₋₄-alkyl, -O-C₁₋₄-alkyl, -C₁₋₄-haloalkyl, -O-(C₁₋₄-alkylene)-**Het**, **Het**, **Hetaryl**, -NH₂,

whereby substituent **X** is further substituted by one, two or three substituents of a group selected from H, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl,

and the pharmaceutically acceptable salts of the aforementioned compounds.

5. The compound of formula **1a** or of formula **1a'** of claim 4, wherein

R¹ is

a) either selected from the group consisting of **Het** and **Hetaryl**;

which is further substituted by one, two or three substituents **Z**,

whereby each **Z** is a substituent independently selected from the group consisting of H, -OH, oxo, -CN, halogen, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -C₁₋₆-haloalkyl, three- to seven-membered cycloalkyl, **Het**, **Hetaryl**, -CO-N(CH₃)₂, -CO-NHCH₃, -CO-NH₂, -(C₁₋₃-alkylene)-O-(C₁₋₃-alkyl), -O-**Het**,

which is further substituted by one, two or three substituents **X**,

whereby each **X** is independently selected from the group consisting of H, halogen, oxo, -C₁₋₄-alkyl,

-O-C₁₋₄-alkyl, -C₁₋₄-haloalkyl, -O-(C₁₋₄-alkylene)-**Het**, **Het**, **Hetaryl**, -NH₂,

whereby substituent **X** is further substituted by one, two or three substituents of a group selected from H, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl,

or wherein **R¹** is

b) phenyl,

which is further substituted by one, two or three substituents **Z**,

whereby each **Z** is a substituent independently selected from the group consisting of, H, -CN, halogen, -C₁₋₆-alkyl, -C₁₋₆-haloalkyl, three- to seven-membered cycloalkyl, **Het**, **Hetaryl**,

which is optionally further substituted by one, two or three substituents **X**,

whereby each **X** is selected from the group consisting of halogen, oxo and -C₁₋₄-alkyl,

and the pharmaceutically acceptable salts of the aforementioned compounds.

6. The compound of formula **1a** or of formula **1a'** of one of claims 4 or 5, wherein

R¹ is either

a monocyclic five- to six-membered heteroaromate with 1, 2 or 3 heteroatoms each independently from one another selected from the group consisting of N, O and S,

or a 9- to 11-membered bicyclic heteroaromate with 1, 2, 3 or 4 heteroatoms each independently from one another selected from the group consisting of N, O and S,

wherein this **R¹** –residue is attached to the rest of the molecule either via a C-atom or via an N-atom and is further substituted by one, two or three substituents **Z**,

whereby each **Z** is a substituent independently selected from the group consisting of

H, -OH, oxo, -CN, halogen, -methyl, -ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, -O-C₁₋₆-alkyl, -C₁₋₆-haloalkyl, three- to seven-membered cycloalkyl, **Het**, **Hetaryl**, -CO-N(CH₃)₂, -CO-NHCH₃, -CO-NH₂, -(C₁₋₃-alkylene)-O-(C₁₋₃-alkyl), -O-**Het**,

which is further substituted by one, two or three substituents **X**,

whereby each **X** is independently selected from the group consisting of H, halogen, oxo, -C₁₋₄-alkyl, -O-C₁₋₄-alkyl, -C₁₋₄-haloalkyl, -O-(C₁₋₄-alkylene)-**Het**, **Het**, **Hetaryl**, -NH₂,

whereby substituent **X** is further substituted by one, two or three substituents of a group selected from H, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl,

and the pharmaceutically acceptable salts of the aforementioned compounds.

7. The compound of formula **1a** or of formula **1a'** according to claim 4, wherein

R¹ is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, thiophenyl, furanyl, pyrazolopyridinyl, indazolyl, thiazolyl, imidazo-pyridinyl and indolyl,

wherein this **R¹** –residue is attached to the rest of the molecule either via a C-atom or via an N-atom and is further substituted by one, two or three substituents **Z**,

whereby each **Z** is a substituent independently selected from the group consisting of

H, -OH, oxo, -CN, halogen, -methyl, -ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, -O-methyl, -O-ethyl, O-propyl, O-butyl, -C₁₋₃-haloalkyl, three-, four, five- or six-membered cycloalkyl, **Het**, **Hetaryl**, -CO-N(CH₃)₂, -CO-NHCH₃, -CO-NH₂, -(C₁₋₃-alkylene)-O-(C₁₋₃-alkyl), -O-**Het**,

which is further substituted by one, two or three substituents **X**,

whereby each **X** is independently selected from the group consisting of H, halogen, oxo, -C₁₋₄-alkyl, -O-C₁₋₄-alkyl, -C₁₋₄-haloalkyl, -O-(C₁₋₄-alkylene)-**Het**, **Het**, **Hetaryl**, -NH₂,

whereby substituent **X** is further substituted by one, two or three substituents of a group selected from H, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl,

and the pharmaceutically acceptable salts of the aforementioned compounds.

8. The compound of formula **1a** or of formula **1a'** according to claim 4, wherein

R¹ is phenyl,

which is further substituted by one, two or three substituents **Z**,

whereby each **Z** is a substituent independently selected from the group consisting of

H, -OH, oxo, -CN, halogen, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -C₁₋₆-haloalkyl, three- to seven-membered cycloalkyl, **Het**, **Hetaryl**, -CO-N(CH₃)₂, -CO-NHCH₃, -CO-NH₂, -(C₁₋₃-alkylene)-O-(C₁₋₃-alkyl), -O-**Het**,


which is further substituted by one, two or three substituents **X**,


whereby each **X** is independently selected from the group consisting of H, halogen, oxo, -C₁₋₄-alkyl, -O-C₁₋₄-alkyl, -C₁₋₄-haloalkyl, -O-(C₁₋₄-alkylene)-**Het**, **Het**, **Hetaryl**, -NH₂,

whereby substituent **X** is further substituted by one, two or three substituents of a group selected from H, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl,

and the pharmaceutically acceptable salts of the aforementioned compounds.


9. The compound of formula **1a** or of formula **1a'** according to claim 4, which is selected from the group consisting of








10. The compound according to claim 9, which is


C[C@H](C1=CC=C2C(=C1)N(C2)C3=CC=CC=C3)Oc4nc5c(ncn5C)cc(C6=CC=CC=C6N7C=CC=CC=C7)c4

12. The compound according to claim 9, which is




176

13. The compound according to claim 9, which is




or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 9, which is




or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 9, which is




or a pharmaceutically acceptable salt thereof.

16. The compound according to claim 9, which is




or a pharmaceutically acceptable salt thereof.

17. The compound of formula **1c** according to claim 1



or of formula **1c'** according to claim 2



wherein

R¹ is selected from the group consisting of
phenyl, **Het** and **Hetaryl**;

which is further substituted by one, two or three substituents **Z**,

whereby each **Z** is a substituent independently selected from the group consisting of

H, -OH, oxo, -CN, halogen, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -C₁₋₆-haloalkyl, three- to seven-membered cycloalkyl, **Het**, **Hetaryl**, -CO-N(CH₃)₂, -CO-NHCH₃, -CO-NH₂, -(C₁₋₃-alkylene)-O-(C₁₋₃-alkyl), -O-**Het**,

which is further substituted by one, two or three substituents **X**,

whereby each **X** is independently selected from the group consisting of H, halogen, oxo, -C₁₋₄-alkyl, -O-C₁₋₄-alkyl, -C₁₋₄-haloalkyl, -O-(C₁₋₄-alkylene)-**Het**, **Het**, -NH₂,

whereby substituent **X** is further substituted by one, two or three substituents of a group selected from H, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl,

and the pharmaceutically acceptable salts of the aforementioned compounds.

18. The compound of formula **1c** or of formula **1c'** of claim 17, wherein

R¹ is

a) either selected from the group consisting of **Het** and **Hetaryl**;

which is further substituted by one, two or three substituents **Z**,

whereby each **Z** is a substituent independently selected from the group consisting of H, -OH, oxo, -CN, halogen, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -C₁₋₆-haloalkyl, three- to seven-membered cycloalkyl, **Het**, **Hetaryl**, -CO-N(CH₃)₂, -CO-NHCH₃, -CO-NH₂, -(C₁₋₃-alkylene)-O-(C₁₋₃-alkyl), -O-**Het**,

which is further substituted by one, two or three substituents **X**,

whereby each **X** is independently selected from the group consisting of H, halogen, oxo, -C₁₋₄-alkyl,

-O-C₁₋₄-alkyl, -C₁₋₄-haloalkyl, -O-(C₁₋₄-alkylene)-**Het**, **Het**, -NH₂,

whereby substituent **X** is further substituted by one, two or three substituents of a group selected from H, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl,

or wherein **R¹** is

b) phenyl,

which is further substituted by one, two or three substituents **Z**,

whereby each **Z** is a substituent independently selected from the group consisting of H, -CN, halogen, -C₁₋₆-alkyl, -C₁₋₆-haloalkyl, three- to seven-membered cycloalkyl, **Het**, **Hetaryl**,

which is further substituted by one, two or three substituents **X**,

whereby each **X** is selected from the group consisting of H, halogen, oxo and -C₁₋₄-alkyl,

and the pharmaceutically acceptable salts of the aforementioned compounds.

19. The compound of formula **1c** or of formula **1c'** according to one of claims 17 or 18, wherein

R¹ is either

a monocyclic five- to six-membered heteroaromate with 1, 2 or 3 heteroatoms each independently from one another selected from the group consisting of N, O and S,

or a 9- to 11-membered bicyclic heteroaromate with 1, 2, 3 or 4 heteroatoms each independently from one another selected from the group consisting of N, O and S,

wherein this **R¹**-residue is attached to the rest of the molecule either via a C-atom or via an N-atom and is further substituted by one, two or three substituents **Z**,

whereby each **Z** is a substituent independently selected from the group consisting of

H, -OH, oxo, -CN, halogen, -methyl, -ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, -O-C₁₋₆-alkyl, -C₁₋₆-haloalkyl, three- to seven-membered cycloalkyl, **Het**, **Hetaryl**, -CO-N(CH₃)₂, -CO-NHCH₃, -CO-NH₂, -(C₁₋₃-alkylene)-O-(C₁₋₃-alkyl), -O-**Het**,

which is further substituted by one, two or three substituents **X**,

whereby each **X** is independently selected from the group consisting of H, halogen, oxo, -C₁₋₄-alkyl, -O-C₁₋₄-alkyl, -C₁₋₄-haloalkyl, -O-(C₁₋₄-alkylene)-**Het**, **Het**, -NH₂,

whereby substituent **X** is further substituted by one, two or three substituents of a group selected from H, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl,

and the pharmaceutically acceptable salts of the aforementioned compounds.

20. The compound of formula **1c** or of formula **1c'** according to claim 17, wherein

R¹ is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, thiophenyl, furanyl, pyrazolopyridinyl, indazolyl, thiazolyl, imidazo-pyridinyl and indolyl,

wherein this **R¹** -residue is attached to the rest of the molecule either via a C-atom or via an N-atom and is further substituted by one, two or three substituents **Z**,

whereby each **Z** is a substituent independently selected from the group consisting of

H, -OH, oxo, -CN, halogen, -methyl, -ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, -O-methyl, -O-ethyl, O-propyl, O-butyl, -C₁₋₃-haloalkyl, three-, four, five- or six-membered cycloalkyl, **Het**, **Hetaryl**, -CO-N(CH₃)₂, -CO-NHCH₃, -CO-NH₂, -(C₁₋₃-alkylene)-O-(C₁₋₃-alkyl), -O-**Het**,

which is further substituted by one, two or three substituents **X**,

whereby each **X** is independently selected from the group consisting of H, halogen, oxo, -C₁₋₄-alkyl, -O-C₁₋₄-alkyl, -C₁₋₄-haloalkyl, -O-(C₁₋₄-alkylene)-**Het**, **Het**, -NH₂,

whereby substituent **X** is further substituted by one, two or three substituents of a group selected from H, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl, and the pharmaceutically acceptable salts of the aforementioned compounds.

21. The compound of formula **1c** or of formula **1c'** according to claim 17, wherein

R¹ is phenyl,

which is further substituted by one, two or three substituents **Z**,

whereby each **Z** is a substituent independently selected from the group consisting of

H, -OH, oxo, -CN, halogen, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -C₁₋₆-haloalkyl, three- to seven-membered cycloalkyl, **Het**, **Hetaryl**, -CO-N(CH₃)₂, -CO-NHCH₃, -CO-NH₂, -(C₁₋₃-alkylene)-O-(C₁₋₃-alkyl), -O-**Het**,



















which is further substituted by one, two or three substituents **X**,


whereby each **X** is independently selected from the group consisting of H, halogen, oxo, -C₁₋₄-alkyl, -O-C₁₋₄-alkyl, -C₁₋₄-haloalkyl, -O-(C₁₋₄-alkylene)-**Het**, **Het**, -NH₂,

whereby substituent **X** is further substituted by one, two or three substituents of a group selected from H, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl,

and the pharmaceutically acceptable salts of the aforementioned compounds.


22. The compound of formula **1c** or of formula **1c'** according to claim 17, which is selected from the group consisting of






and the pharmaceutically acceptable salts of the aforementioned compounds.

23. The compound according to claim 22, which is




or a pharmaceutically acceptable salt thereof.

24. The compound according to claim 22, which is




or a pharmaceutically acceptable salt thereof.

25. The compound according to claim 22, which is




or a pharmaceutically acceptable salt thereof.

26. The compound according to claim 22, which is




or a pharmaceutically acceptable salt thereof.


27. An intermediate compound selected from the group consisting of formula 6




of formula 7



of formula **8**



and of formula **11**




wherein **E**, **D**, **G**, **T** and **R¹** are defined as in claim 1 and wherein **Hal** is Cl or Br

and wherein **X** is -B(OH)_2 , -boronic acid pinacolester, -trifluoroborate or -SNBu_3
and wherein **PG** is a protecting group selected from the group consisting of benzyl, 1-phenylethyl, 1-(4-methoxyphenyl)ethyl.

28. An intermediate compound selected from the group consisting of

formula 10.2



29. The compound of any of claims 1 to 26 for use in the treatment of a disease which can be treated by inhibition of the SYK enzyme.
30. The compound of any of claim 1 to 26 for use in the treatment of a disease selected from the group consisting of allergic rhinitis, asthma, COPD, adult respiratory distress syndrome, bronchitis, B-cell lymphoma, dermatitis and contact dermatitis, allergic dermatitis, allergic rhinoconjunctivitis, rheumatoid arthritis, anti-phospholipid syndrome, Berger's disease, Evans's syndrome, ulcerative colitis, allergic antibody-based glomerulonephritis, granulocytopenia, Goodpasture's syndrome, hepatitis, Henoch-Schönlein purpura, hypersensitivity vasculitis, immunohaemolytic anaemia, autoimmune haemolytic anemia, idiopathic thrombocytopenic purpura, Kawasaki syndrome, allergic conjunctivitis, lupus erythematoses, lupus nephritis, capsule cell lymphoma, neutropenia, non-familial lateral sclerosis, arteriosclerosis, Crohn's disease, multiple sclerosis, myasthenia gravis, osteoporosis, osteolytic diseases,

osteopenia, psoriasis, Sjögren's syndrome, sclerodermy, T-cell lymphoma, urticaria / angiooedema, Wegener's granulomatosis and coeliac disease.

- 31.** The compound of any of claim 1 to 26 for use in the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, adult respiratory distress syndrome, bronchitis, allergic dermatitis, contact dermatitis, idiopathic thrombocytopenic purpura, rheumatoid arthritis, lupus erythematoses, lupus nephritis and allergic rhinoconjunctivitis.
- 32.** The compound of any of claim 1 to 26 for use in the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematoses, lupus nephritis and rheumatoid arthritis.
- 33.** Pharmaceutical formulations, characterised in that they contain one or more compounds according to one of claims 1 to 26 and a pharmaceutically acceptable excipient.
- 34.** Pharmaceutical formulations, characterised in that they contain one or more compounds according to one of claims 1 to 26 in combination with an active substance selected from the group consisting of anticholinergics, betamimetics, corticosteroids, PDE4-inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, CRTH2-antagonists, HMG-CoA reductase inhibitors and NSAIDs.
- 35.** Use of the compound of any of claim 1 to 26 in the manufacture of a medicament for the treatment of a disease selected from the group consisting of allergic rhinitis, asthma, COPD, adult respiratory distress syndrome, bronchitis, B-cell lymphoma, dermatitis and contact dermatitis, allergic dermatitis, allergic rhinoconjunctivitis, rheumatoid arthritis, anti-phospholipid syndrome, Berger's disease, Evans's syndrome, ulcerative colitis, allergic antibody-based glomerulonephritis, granulocytopenia, Goodpasture's syndrome, hepatitis, Henoch-Schönlein purpura, hypersensitivity vasculitis,

immunohaemolytic anaemia, autoimmune haemolytic anemia, idiopathic thrombocytopenic purpura, Kawasaki syndrome, allergic conjunctivitis, lupus erythematoses, lupus nephritis, capsule cell lymphoma, neutropenia, non-familial lateral sclerosis, arteriosclerosis, Crohn's disease, multiple sclerosis, myasthenia gravis, osteoporosis, osteolytic diseases, osteopenia, psoriasis, Sjögren's syndrome, sclerodermy, T-cell lymphoma, urticaria / angioedema, Wegener's granulomatosis and coeliac disease.

- 36.** Use of the compound of any of claim 1 to 26 in the manufacture of a medicament for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, adult respiratory distress syndrome, bronchitis, allergic dermatitis, contact dermatitis, idiopathic thrombocytopenic purpura, rheumatoid arthritis, lupus erythematoses, lupus nephritis and allergic rhinoconjunctivitis.
- 37.** Use of the compound of any of claim 1 to 26 in the manufacture of a medicament for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematoses, lupus nephritis and rheumatoid arthritis.